New Risk • Jun 05
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (AU$413k revenue, or US$292k). Market cap is less than US$10m (US$5.51m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change). Announcement • May 23
Gelteq Limited Commences Clinical Trial For Antiparasitic Drug Candidate Powered By Gelteq Technology Gelteq Limited commenced its first clinical trial for an antiparasitic drug candidate powered by Gelteq technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector. The clinical trial seeks to support Gelteq’s planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026. Commencement of the clinical trial builds on Gelteq’s prior announcement regarding the FDA’s acceptance of its suitability petition, representing a key step in progressing the antiparasitic drug candidate powered by Gelteq technology toward regulatory approval. The trial is expected to generate critical data to support the safety, efficacy, and formulation performance of Gelteq technology in an animal health setting. With the clinical trial now underway, Gelteq intends to generate data that will support both regulatory progression and future commercial opportunities within the veterinary sector. The global animal health market is estimated to exceed USD 78 billion in 2026, with antiparasitic treatments representing a significant segment driven by increasing pet ownership and ongoing demand for parasite prevention and control. As Gelteq advances this program toward potential regulatory approval, the Company believes it is strategically positioned to participate in a large and growing market segment, where improved delivery formats may offer meaningful advantages in compliance and dosing. With Gelteq’s recent financing, the Company believes it is well positioned with sufficient capital to execute on its dual-track strategy of advancing pharmaceutical programs for long-term value while continuing to drive near-term revenue through its commercial nutraceutical portfolio. New Risk • Apr 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (AU$413k revenue, or US$285k). Market cap is less than US$10m (US$7.27m market cap). 
